-
161
-
162
Immune-checkpoint-inhibitor therapy directed against PD-L1 is tolerated in the heart without manifestation of cardiac inflammation in a preclinical reversible melanoma mouse model
Published 2025-01-01“…Without a second hit that triggers the inflammatory response, anti-PD-L1 treatment appears to be safe for the heart in the preclinical melanoma mouse model.…”
Get full text
Article -
163
-
164
-
165
Pre-treatment subjective sleep quality as a predictive biomarker of tDCS effects in preclinical Alzheimer's disease patients: Secondary analysis of a randomised clinical trial.
Published 2025-01-01“…More thorough research is necessary to explore an efficient approach to managing comorbidities for preclinical AD patients.…”
Get full text
Article -
166
Clinical-grade extracellular vesicles derived from umbilical cord mesenchymal stromal cells: preclinical development and first-in-human intra-articular validation as therapeutics for knee osteoarthritis
Published 2025-01-01“…This study provides data on using UC-MSC-sEV as local therapy for OA, highlighting their regenerative and anti-inflammatory properties and safety in preclinical and a proof-of-principle clinical application. …”
Get full text
Article -
167
-
168
Disruption of Gut Microbiota and Associated Fecal Metabolites in Collagen-Induced Arthritis Mice During the Early Stage
Published 2025-02-01Subjects: Get full text
Article -
169
Validation framework for in vivo digital measures
Published 2025-01-01Subjects: Get full text
Article -
170
-
171
Adjuvant properties of chitosan derivatives administered to mice with anti-rabies vaccine
Published 2024-06-01Subjects: Get full text
Article -
172
-
173
Validation of an MPS-based intestinal cell culture model for the evaluation of drug-induced toxicity
Published 2025-01-01Subjects: Get full text
Article -
174
Unwanted disorders and xenogeneic graft‐versus‐host disease in experimental immunodeficient mice: How to evaluate and how to report
Published 2025-01-01Subjects: Get full text
Article -
175
Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer
Published 2024-07-01“…Objective To evaluate signal transducer and activator of transcription 3 (STAT3) inhibition we conducted a co-clinical trial testing danvatirsen, a STAT3 antisense oligonucleotide (ASO) and checkpoint inhibition in conjunction with preclinical experiments.Methods and analysis Orthotopically implanted pancreatic cancer (pancreatic adenocarcinoma (PDAC)) was treated with STAT3 ASO with immune checkpoint inhibition. …”
Get full text
Article -
176
-
177
-
178
The neighborhood walk: introducing first-year medical students to social determinants of health in underserved neighborhoods
Published 2025-01-01Subjects: Get full text
Article -
179
Antitumor effect of a new human epidermal growth factor receptor inhibitor
Published 2024-09-01Subjects: Get full text
Article -
180